AlloVir (ALVR) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChart

AlloVir Revenue Highlights


00

Main Segment (Y)

Grant

Main Geography (Y)

Grant

AlloVir Revenue by Period


AlloVir Revenue by Year

DateRevenueChange
2023-12-31-100.00%
2022-12-31-100.00%
2021-12-31-100.00%
2020-12-31--100.00%
2019-12-31$165.00K-85.46%
2018-12-31$1.14M-

AlloVir generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

AlloVir Revenue by Quarter

DateRevenueChange
2024-06-30-100.00%
2024-03-31--100.00%
2023-12-31$8.38M100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30--100.00%
2019-03-31$165.00K-

AlloVir generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

AlloVir Revenue Breakdown


AlloVir Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 20
Grant$900.00K

AlloVir's latest annual revenue breakdown by segment (product or service), as of Dec 20: Grant (100.00%).

Quarterly Revenue by Product

Product/ServiceDec 20Sep 20Jun 20
Grant$200.00K$400.00K$300.00K

AlloVir's latest quarterly revenue breakdown by segment (product or service), as of Dec 20: Grant (100.00%).

AlloVir Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 20
Grant$900.00K

AlloVir's latest annual revenue breakdown by geography, as of Dec 20: Grant (100.00%).

Quarterly Revenue by Country

CountryDec 20Sep 20Jun 20
Grant$200.00K$400.00K$300.00K

AlloVir's latest quarterly revenue breakdown by geography, as of Dec 20: Grant (100.00%).

AlloVir Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
MRUSMerus$43.95M$11.77M
AGIOAgios Pharmaceuticals$26.82M$8.96M
ADAGAdagene$18.11M$833.34K
ANABAnaptysBio$17.16M$10.97M
STOKStoke Therapeutics$8.78M$4.22M
KRONKronos Bio$6.29M$2.69M
CRNXCrinetics Pharmaceuticals$4.01M$640.00K
INBXInhibrx Biosciences$1.80M-
FIXXQ32 Bio$1.16M-
BCELAtreca$770.00K$80.00K
LYELLyell Immunopharma$130.00K$3.00K
ANEBAnebulo Pharmaceuticals--
CGEMCullinan Oncology--
ALVRAlloVir--
BDTXBlack Diamond Therapeutics--
ANTXAN2 Therapeutics--
AVTEAerovate Therapeutics--
ACRVAcrivon Therapeutics--
MLYSMineralys Therapeutics--
FDMT4D Molecular Therapeutics--

ALVR Revenue FAQ


AlloVir's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. ALVR's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.

AlloVir's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). ALVR's quarterly revenue for Q4 2023 was $8.38M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).

AlloVir's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was -100.00%.

AlloVir's revenue streams in c 20 are Grant

For the fiscal year ending Dec 20, the largest source of revenue of AlloVir was Grant. This segment made a revenue of $900K, representing 100.00% of the company's total revenue.